Findings seen among pediatric patients presenting to the emergency department with moderate-to-severe acute pain ...

Officials say low vaccination rates in rural communities are fueling the spread of the highly contagious virus.

Phase 3 HER2CLIMB-05 trial demonstrates a 35.9% reduction in risk of disease progression or death with maintenance tucatinib combination.

Serum ferritin threshold of less than or equal to 20ng/mL is suggested for children ages 9 months to 4 years. HealthDay News — In guidelines issued by the American Society of Hematology and published ...

Nearly 1 in 3 patients with systemic lupus erythematosus (SLE) are taking a supplement–medication combination with potential for an interaction, according to ...

The novel GPR6 inhibitor met its primary endpoint in the phase 3 ARISE trial, achieving a statistically significant reduction in daily OFF time and demonstrating non-dopaminergic motor and ...

The approval makes remibrutinib the first targeted therapy approved for symptomatic dermographism, expanding its indication beyond chronic spontaneous urticaria.

In national prospective study, 2.9% of those undergoing anesthesia reported receiving GLP-1 receptor agonists.

Phase 3 PROPEL 3 trial results show daily oral infigratinib significantly improved annualized height velocity and height Z-scores compared with placebo in children with achondroplasia.

FDA clearance of Motivista introduces a novel prescription digital therapeutic specifically indicated to target experiential negative symptoms in adults with schizophrenia.

Combined tobacco and e-cigarette exposure linked to increase in activity-related symptoms, nighttime symptoms, albuterol use.

Phase 3b trial shows long-acting injectable therapy outperforms daily oral regimens for patients with detectable HIV-1 and adherence challenges.